Citations

Clear

479 citation(s) found for "Tobias, JS".

Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Wen, Patrick Y. , Lee, Eudocia Q. , Khasraw, Mustafa , Rahman, Rifaquat , Platten, Michael , Lim, Michael , Verhaak, Roel G.W. , Albert, Nathalie L. , Schiff, David , Ostrom, Quinn T. , Aldape, Kenneth , Batchelor, Tracy T. , Chiocca, E. Antonio, DeGroot, John, French, Pim J. , Hegi, Monika E. , Lassman, Andrew B. , Mellinghoff, Ingo K. , Minniti, Giuseppe, Taphoorn, Martin , Weiss, von Deimling, Tobias, Zadeh, Gelareh , Reardon, David A. , Chang, Susan M. , Short, Susan , Weller, Michael , Touat, Mehdi , Khasraw, Mustafa , Platten, Michael , Winkler, Frank , Verhaak, Roel Gw , Albert, Nathalie L , Tonn, Joerg-Christian , Barnholtz-Sloan, Jill S , Cloughesy, Timothy F , French, Pim J , Galanis, Evanthia , Galldiks, Norbert , Mellinghoff, Ingo K , Roth, Patrick , Sanson, Marc , Wick, Wolfgang , Reardon, David A , Short, Susan C , Ostrom, Quinn T , Wen, Patrick Yung , Horbinski, Craig , Huang, Raymond Y. , Ahluwalia, Manmeet S. , Barnholtz‐Sloan, Jill S. , Bindra, Ranjit S. , Cloughesy, Timothy F. , Galanis, Evanthia , Gilbert, Mark R. , Rhun, Émilie Le , Mehta, Minesh P. , Roth, Patrick , Sanson, Marc , Weiss, von Deimling, Tobias, Wick, Wolfgang , Bent, Martin J. van den , Preusser, Matthias

Mayo Clinic

Neuro-Oncology | July 22, 2025 | Volume: 27 | Issue: 11 | Pages: 2751-2788

10.1093/neuonc/noaf177 | PMID 40827022 Get It

Abstract Glioblastoma is the most common type of malignant primary brain tumor and a major cause of morbidity and mortality. In 2021, the World Health Organization updated the classification of Central Nervous System (CNS) tumors to restrict glioblastomas to isocitrate dehydrogenase-wildtype (IDHwt) tumors, improving understanding of the prognosis and optimal therapy for these tumors. This revision also enables more homogeneous populations of patients to be enrolled in clinical trials, facilitating the evaluation of novel therapies. In this updated consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO), the current management of patients with glioblastoma is discussed. In addition, novel therapies such as immunotherapies, viral therapies, targeted molecular therapies, theranostics, and antibody–drug conjugates will be reviewed, as well as the current challenges and future directions for research.
Roadblocks of Urinary EV Biomarkers: Moving Toward the Clinic
Droste, Marvin , Puhka, Maija , Ng, Monica Suet Ying , Álvarez‐Llamas, Gloria , Borràs, Francesc E. , Büscher, Anja , Bussolati, Benedetta , Dear, James W. , Hoorn, Ewout J. , Lenassi, Metka , Pink, Desmond , Tiwari, Swasti , Vizio, Dolores Di , Zarovni, Nataša , Martens‐Uzunova, Elena S. , Erdbrügger, Uta , Ng, Monica S Y , Alvarez-Llamas, Gloria , Borràs, Francesc E , Bussolati, Benedetta , Falcón-Perez, Juan Manual , Lenassi, Metka , Lucien, Fabrice , Tertel, Tobias , Martens-Uzunova, Elena S , Royen, Martin E. van , Blijdorp, Charles J. , Falcón‐Pérez, Juan Manuel , Giebel, Bernd , Grange, Cristina , Leivo, Janne , Llorente, Alicia , Lucien, Fabrice , Mertens, Inge , Mischak, Harald , Yuen, Peter S.T. , Jenster, Guido , Burger, Dylan

Mayo Clinic

Journal of Extracellular Vesicles | July 17, 2025 | Volume: 14 | Issue: 7 | Pages: No page available

10.1002/jev2.70120 | PMID 40673839 Get It

ABSTRACT Despite remarkable interest in the biomarker potential of urinary extracellular vesicles (uEVs) and the identification of numerous promising candidates, their clinical translation still presents multiple challenges. The opportunities for successful translation are obvious, yet the main roadblocks on the way have hardly been systematically considered and more coordinated approaches are needed to overcome them. In the present review article, we have identified the most relevant roadblocks of clinical translation of urinary EV‐based biomarkers and discuss possible solutions to overcome them. These roadblocks are categorized as fundamental and technical but also related to development of novel biomarker assays and clinical acceptance. In addition, hurdles within the regulatory approval process are discussed. It is clear that various roadblocks to clinical translation of urinary EV biomarkers exist; however, they are addressable by promoting rigor and reproducibility as well as collaboration between basic and clinical scientists, clinicians, industry and regulatory bodies. Moreover, knowledge of obstacles for assay development and regulatory requirements should already be considered when developing a new biomarker to maximize the chance of successful translation. This review presents not only a status quo, but also a roadmap for the further development of the field.
Baseline predictors of poor clinical outcome despite recanalization of distal middle cerebral artery occlusions
Chafai, Imene , Salim, Hamza , Musmar, Basel , Adeeb, Nimer , Yedavalli, Vivek , Tjoumakaris, Stavropoula , Henninger, Nils , Nedelcu, Simona , Sundararajan, Sri Hari , Kühn, Anna Luisa , Khalife, Jane , Tan, Benjamin Yong‐Qiang , Heit, Jeremy J. , Regenhardt, Robert W. , Puri, Ajit S , Dyzmann, Christian , Filipe, João Pedro , Marotta, Thomas R. , Spears, Julian , Biswas, Arundhati , Clarençon, Frédéric , Varela, Ricardo , Baker, Amanda , Altschul, David , Gonzalez, Nestor R. , Möhlenbruch, Markus , Costalat, Vincent , Stracke, Christian Paul , Shaikh, Hamza , Liebeskind, David S. , Alexandre, Andrea , Tancredi, Illario , Faizy, Tobias D. , Kalsoum, Erwah , Patel, Aman B. , Wang, Maud , Lubicz, Boris , Guenego, Adrien , ##, On behalf of the MAD MT Investigators, Tjoumakaris, Stavropoula , Ghozy, Sherief , Scarcia, Luca , Tan, Benjamin Yq , Heit, Jeremy J , Regenhardt, Robert W , Cancelliere, Nicole M , Bernstock, Joshua D , Rouchaud, Aymeric , Fiehler, Jens , Sheth, Sunil A , Essibayi, Muhammed Amir , Colasurdo, Marco , Marnat, Gaultier , Renieri, Leonardo , Filipe, João Pedro , Harker, Pablo , Alexandru Radu, Răzvan , Marotta, Thomas R , Spears, Julian , Ota, Takahiro , Mowla, Ashkan , Jabbour, Pascal , Clarençon, Frédéric , Nguyen, Thanh N , Varela, Ricardo , Altschul, David J , Gonzalez, Nestor R , Möhlenbruch, Markus A , Gory, Benjamin , Stracke, Paul , Hecker, Constantin , Shaikh, Hamza A , Liebeskind, David S. , Pedicelli, Alessandro , Alexandre, Andrea M , Tancredi, Illario , Faizy, Tobias D , Kalsoum, Erwah , Fahed, Robert , Wang, Maud , Mendes Pereira, Vitor , Lubicz, Boris , Dmytriw, Adam A , Guenego, Adrien , Kühn, Anna Luisa , Musmar, Basel , Salim, Hamza , Yedavalli, Vivek S , Henninger, Nils , Nedelcu, Simona , Ghozy, Sherief , Cancelliere, Nicole M , Bernstock, Joshua D. , Rouchaud, Aymeric , Fiehler, Jens , Essibayi, Muhammed Amir , Colasurdo, Marco , Renieri, Leonardo , Harker, Pablo , Radu, Răzvan Alexandru , Mowla, Ashkan , Jabbour, Pascal , Nguyen, Thanh N. , Baker, Amanda, Aziz‐Sultan, Mohammad Ali , Hecker, Constantin , Fahed, Robert , Dmytriw, Adam A. , ##, On behalf of the MAD MT Investigators

Mayo Clinic

Interventional Neuroradiology | July 16, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15910199251342841 | PMID 40665742 Get It

Objective Mechanical thrombectomy (MT) is well-established for the treatment of acute ischemic stroke (AIS) from large vessel occlusion (LVO), with growing data supporting the expansion to distal and medium vessel occlusions (DMVO). Despite successful recanalization in DMVO, certain patients still experience poor long-term clinical outcomes, prompting our study to comprehensively explore pre-MT factors influencing outcome despite excellent recanalization (final modified Thrombolysis in Cerebral Infarction [mTICI] score ≥2c). Methods We retrospectively examined data from patients who consecutively underwent MT for a primary middle cerebral artery (MCA) DMVO across 37 centers in North America, Asia, and Europe. We identified baseline clinical and imaging factors associated with poor clinical outcome (defined as a modified Rankin Scale [mRS] score of 3–6) at 3 months, despite excellent recanalization using a multivariable model. Results Between September 2017 and July 2021, 623 patients achieved mTICI > 2b and they were included in our study. Among them, 198 (32%) experienced a poor clinical outcome (mRS 3–6). Predictors of poor clinical outcome included higher age (OR 1.05 [1.03–1.07], p < 0.001), higher NIHSS at admission (OR 1.12 [1.08–1.15], p < 0.001), higher baseline mRS (OR 1.77 [0.96–3.26], p = 0.067), and diabetes (OR 1.59 [1.01–2.48], p = 0.044). Higher ASPECTS was associated with a decreased risk of poor clinical outcome (OR 0.82 [0.71–0.94], p = 0.006). Conclusion Older age, diabetes, higher baseline mRS, and NIHSS were associated with poor clinical outcome in MCA DMVO despite excellent recanalization. Conversely, a higher ASPECTS decreased the probability of such an outcome.
Petechial hemorrhage in mechanical thrombectomy for distal and medium-vessel occlusions: technical considerations and outcomes
Baker, Amanda , Adeeb, Nimer , Henninger, Nils , Sundararajan, Sri Hari , Khalife, Jane, Tan, Benjamin Yong‐Qiang , Regenhardt, Robert W. , Heit, Jeremy J. , Cancelliere, Nicole M., Fiehler, Jens, Puri, Ajit S., Dyzmann, Christian , Colasurdo, Marco, Filipe, João Pedro , Harker, Pablo, Abdalkader, Mohamad , Marotta, Thomas R. , Spears, Julian , Jabbour, Pascal , Biswas, Arundhati , Clarençon, Frédéric , Varela, Ricardo , Gonzalez, Nestor R. , Möhlenbruch, Markus , Costalat, Vincent , Gory, Benjamin , Yedavalli, Vivek , Stracke, Christian Paul , Shaikh, Hamza, Liebeskind, David S., Alexandre, Andrea , Faizy, Tobias D., Tancredi, Illario , Kalsoum, Erwah , Lubicz, Boris , Patel, Aman B. , Guenego, Adrien , Altschul, David , _, _, Amllay, Abdelaziz, Gopinathan, Anil, Dusart, Anne , Capirossi, Carolina , Mounayer, Charbel, Hsieh, Cheng-Yang, Stapleton, Christopher J. , Bellante, Flavio, Shaikh, Hamza , Cuellar-Saenz, Hugo H., Rabinov, James D. , Berge, Jérôme , Martinez-Gutierrez, Juan Carlos, Premat, Kévin , Chervak, Lina , Elhorany, Mahmoud, Quintero‐Consuegra, Miguel , Kan, Peter , Khandelwal, Priyank , Kadirvel, Ramanathan , Dofuku, Shogo , Nedelcu, Simona, Tjoumakaris, Stavropoula I, Barreau, Xavier, Liebeskind, David S. , Liebeskind, David S. , Heit, Jeremy J , Altschul, David J , Gonzalez, Nestor R , Regenhardt, Robert W , Yedavalli, Vivek S , Henninger, Nils , Tan, Benjamin Yq , Alexandre, Andrea M , Varela, Ricardo , Essibayi, Muhammed Amir , Salim, Hamza , Fazzari, Melissa J. , Khatri, Deepak , Baker, Amanda, Musmar, Basel , Kühn, Anna Luisa , Khalife, Jane , Ghozy, Sherief , Scarcia, Luca , Yeo, Leonard Ll , Cancelliere, Nicole M , Rouchaud, Aymeric , Sheth, Sunil A , Puri, Ajit S , Colasurdo, Marco , Renieri, Leonardo , Harker, Pablo , Aziz, Yasmin , Radu, Răzvan Alexandru , Klein, Piers , Ota, Takahiro , Mowla, Ashkan , Naamani, Kareem El , Jabbour, Pascal , Siegler, James E. , Nguyen, Thanh N. , Gory, Benjamin , Hecker, Constantin , Marnat, Gaultier , Griessenauer, Christoph J. , Pedicelli, Alessandro , Faizy, Tobias D. , Mendes Pereira, Vitor , Dmytriw, Adam A. , _, _, Amllay, Abdelaziz , Vagal, Achala , Schiphorst, Adrien ter , Thomas, Ajith J , Mounayer, Charbel , Weyland, Charlotte S. , Hsieh, Cheng‐Yang , Forestier, Géraud , Cuellar, Hugo , Valente, Iacopo , Sibon, Igor , Jesser, Jessica , Martinez-Gutierrez, Juan Carlos , Meyer, Lukas , Elhorany, Mahmoud , Aziz‐Sultan, Mohammad Ali , Killer-Oberpfalzer, Monika , Khandelwal, Priyank , Fahed, Robert , Salazar‐Marioni, Sergio , Nedelcu, Simona , Tjoumakaris, Stavropoula , Saleme, Suzana , Barreau, Xavier

Mayo Clinic

Journal of Neurosurgery | July 4, 2025 | Volume: 143 | Issue: 6 | Pages: 1501-1513

10.3171/2025.3.jns243030 | PMID 40614268 Get It

OBJECTIVE Mechanical thrombectomy (MT) is well established for large-vessel occlusion (LVO) strokes, but its safety in distal and medium-vessel occlusions (DMVOs) requires further investigation. This study analyzed the relationship between procedural approaches, petechial hemorrhage (PetH), and clinical outcomes in DMVO thrombectomy, with particular attention to technical considerations and the complex interplay between tissue injury and hemorrhagic complications. METHODS A retrospective cohort study was conducted on DMVO stroke patients treated with MT at 37 stroke centers worldwide from 2016 to 2024. Patients were categorized based on follow-up imaging into those with or without PetH. Four logistic regression models analyzed the association of PetH with favorable functional outcomes (modified Rankin Scale score ≤ 2) at 90 days, early neurological improvement (≥ 4-point National Institutes of Health Stroke Scale score decrease at 24 hours), all-cause mortality, and independent determinants of PetH. Adjusted odds ratios (aORs), 95% confidence intervals, and p values were reported. RESULTS Of 1428 patients, 439 (30.7%) developed PetH. Factors independently associated with PetH were multiple thrombectomy passes (aOR 1.58, 95% CI 1.21–2.06; p = 0.001), IV thrombolysis (aOR 1.31, 95% CI 1.01–1.69; p = 0.04), and the combined use of a stent retriever with aspiration as the first-line method compared with aspiration alone (aOR 1.66, 95% CI 1.15–2.38; p = 0.007). Conversely, general anesthesia (aOR 0.55, 95% CI 0.40–0.77; p < 0.001), higher Alberta Stroke Program Early CT Scores (aOR 0.76, 95% CI 0.69–0.83; p < 0.001), and successful recanalization (aOR 0.56, 95% CI 0.39–0.80; p = 0.002) were significantly associated with a lower odds of PetH. PetH was associated with a decreased odds of favorable functional outcomes (aOR 0.51, 95% CI 0.36–0.73; p < 0.001), reduced early neurological improvement (aOR 0.59, 95% CI 0.44–0.79; p < 0.001), and increased all-cause mortality (aOR 1.84, 95% CI 1.23–2.76; p < 0.001). CONCLUSIONS PetH is a frequent sequela following MT in DMVO strokes and is associated with poorer outcomes, likely reflecting underlying ischemic injury rather than direct causation. Procedural factors influence PetH risk, suggesting medical treatment as first-line therapy for DMVOs, with MT reserved for refractory cases using less aggressive approaches.
Pathologist-Read vs AI-Driven Assessment of Tumor-Infiltrating Lymphocytes in Melanoma
Liu, Matthew , Steen, Sanna , Tsiknakis, Nikolaos, Vidal, Joan Martínez , Maher, Nigel G. , Tan, Samuel , Bai, Yalai , Wong, Pok Fai , Gavirelatou, Niki, He, Mengni , Barna, Robert , Bosić, Martina , Bräutigam, Konstantin , Chenhao, Zhou, Gama, João Martins , Kreis, Bianca, Mohácsi, Réka , Pillar, Nir , Poulios, Christos , Toli, Maria Angeliki , Tzoras, Evangelos , Bracero, Yadriel , Bosisio, Francesca M. , Fortarezza, Francesco , Gonzalez, Mercedes Solorzano, Gullo, Irene , Gutiérrez, Francisco Javier Queipo , Hacıhasanoğlu, Ezgi , Jović, Viktor , Lazar, Bianca Andreea, Neppl, Christina, Pinto, Daniel , Plótár, Vanda, Rau, Tilman T. , Skok, Kristijan , Sun, Wenwen , Solaß, Wiebke , Szymoński, K , Thimm, Franziska , Vignati, Danielle, Vigdorovits, Alon , Prieto, Víctor G. , Sinnberg, Tobias , Wilmott, James S. , Cowper, Shawn E. , Hartman, Johan , Osman, Iman , Ács, Balázs , Nourmohammadi, Saeed, Acs, Balazs , Hartman, Johan , Aung, Thazin Nwe , Su, David , Shafi, Saba , Boyacı, Ceren , Tsiknakis, Nikos , Micevic, Goran , Vesely, Matthew D. , Nourmohammadi, Saeed , Djureinovic, Dijana , Bates, Katherine, Chan, Nay Nwe Nyein , Burela, Sneha , Illa-Bochaca, Irineu , Kreis, Bianca, Pinto, João Correia , Cserni, Gábor , Dema, Alis Liliana Carmen , Gonzalez, Mercedes Solorzano, Olincă, Maria , Oliveira, Rui Caetano , Pezzuto, Federica , Pop, Ovidiu Laurean , Serbes, Ezgi Dicle , Stanowska, Olga , Szász, Attila Marcell , Warrell, Jonathan , Saenger, Yvonne M. , Plummer, Jasmine , Rimm, David L.

Mayo Clinic

JAMA Network Open | July 3, 2025 | Volume: 8 | Issue: 7 | Pages: e2518906

10.1001/jamanetworkopen.2025.18906 | PMID 40608341 Get It

Importance Tumor-infiltrating lymphocytes (TILs) are a provocative biomarker in melanoma, influencing diagnosis, prognosis, and immunotherapy outcomes; however, traditional pathologist-read TIL assessment on hematoxylin and eosin–stained slides is prone to interobserver variability, leading to inconsistent clinical decisions. Therefore, development of newer TIL scoring approaches that produce more reliable and consistent readouts is important. Objective To evaluate the analytical and clinical validity of a machine learning algorithm for TIL quantification in melanoma compared with traditional pathologist-read methods. Design, Setting, and Participants This multioperator, global, multi-institutional prognostic study compared TIL scoring reproducibility between traditional pathologist-read methods and an artificial intelligence (AI)-driven approach. The study was conducted using retrospective cohorts of patients with melanoma between January 2022 and June 2023 across 45 institutions, with tissue evaluated by participants from academic, clinical, and research institutions. Participants were selected to ensure diverse expertise and professional backgrounds. Main Outcomes and Measures Intraclass correlation coefficient (ICC) values were calculated for the manual and AI-assisted arms using log-transformed data. Kendall W values were calculated for Clark scores (brisk = 3, nonbrisk = 2, and sparse = 1). Reliabilities of ICC and W values were classified as moderate (0.40-0.60), good (0.61-0.80), or excellent (&amp;gt;0.80). AI TIL measurements were dichotomized using the 16.6 and median cutoffs. Univariable and multivariable Cox regression analyses assessed the prognostic value of TIL scores adjusted for clinicopathologic variables. Results There were 111 patients with melanoma in the independent testing cohort (median [range] age at diagnosis, 61.0 [25.0-87.0] years; 56 [50.5%] male) who contributed melanoma whole tissue sections. A total of 98 participants evaluated TILs on 60 hematoxylin and eosin–stained melanoma tissue sections. All 40 participants in the manual arm were pathologists, while the AI-assisted arm included 11 pathologists and 47 nonpathologists (scientists). The AI algorithm demonstrated superior reproducibility, with ICCs higher than 0.90 for all machine learning TIL variables, significantly outperforming manual assessments (ICC, 0.61 for AI-derived stromal TILs vs Kendall W , 0.44 for manual Clark TIL scoring). AI-based TIL scores showed prognostic associations with patient outcomes (n = 111) using the median cutoff approach with a hazard ratio (HR) of 0.45 (95% CI, 0.26-0.80; P = .005), and using the cutoff of 16.6, with an HR of 0.56 (95% CI, 0.32-0.98; P = .04). Conclusions and Relevance In this prognostic study of TIL quantification in melanoma, the AI algorithm demonstrated superior reproducibility and prognostic associations compared with traditional methods. Although the retrospective nature of the cohorts limits demonstration of clinical utility, the publicly available dataset and open-source AI tool offer a foundation for future validation and integration into melanoma management.
Sexual outcomes following Rezum therapy with and without median lobe resection
Hashemi, Milad Bonakdar , Lozoya, Andres H Guillen, Pinkhasov, Alexandr, Köhler, Tobias , Guillen Lozoya, Andres H, Pinkhasov, Alexandr M

Mayo Clinic

The Journal of Sexual Medicine | June 26, 2025 | Volume: 22 | Issue: 8 | Pages: 1523-1524

10.1093/jsxmed/qdaf151 | PMID 40570545 Get It

Comparative effectiveness of second‐line treatments for epileptic spasms
Barbour, Kristen , Hussain, Shaun A. , Knupp, Kelly G. , Chu, Catherine J. , Coryell, Jason , Fernández, Iván Sánchez , Gaillard, William D. , Harini, Chellamani , Keator, Cynthia, Mitchell, Wendy G. , Mytinger, John R. , Nordli, Douglas R. , Shellhaas, Renée A. , Singhal, Nilika S. , Valencia, Ignacio , Wusthoff, Courtney J. , Chu, Catherine J , Coryell, Jason , Gaillard, William D , Mytinger, John R , Patel, Anup D , Shellhaas, Renée A , Wirrell, Elaine C , Wusthoff, Courtney J , Yozawitz, Elissa G , Grinspan, Zachary , Hussain, Shaun A , Knupp, Kelly G , Berg, Anne T. , Loddenkemper, Tobias , Patel, Anup D. , Wirrell, Elaine , Yozawitz, Elissa , Grinspan, Zachary M.

Mayo Clinic

Epilepsia | June 18, 2025 | Volume: 66 | Issue: 10 | Pages: 3799-3809

10.1111/epi.18511 | PMID 40528701 Get It

Abstract Objective This study was undertaken to evaluate the response to second treatments for infantile epileptic spasms syndrome (IESS). Methods Infants aged 2–24 months with IESS were prospectively enrolled in the National Infantile Spasms Cohort study at 21 pediatric epilepsy centers in the United States from 2012 to 2018. We analyzed data from infants who initially received standard treatment (hormonal therapy [adrenocorticotropic hormone, high‐dose prednisolone] or vigabatrin), had continued or recurring epileptic spasms, and received a second treatment. We excluded those with tuberous sclerosis. Treatment groups included hormonal therapy followed by vigabatrin (reference), hormonal‐to‐hormonal, hormonal‐to‐nonstandard, vigabatrin‐to‐hormonal, and vigabatrin‐to‐nonstandard. Nonstandard treatments included other antiseizure medications and dietary therapy. Treatment groups were tested for differences in 3‐month clinical remission using a binary logistic regression to estimate odds ratios (ORs). Results There were 153 infants with IESS who received second treatments. The highest rates of 3‐month remission were among infants in the hormonal‐to‐vigabatrin (22/65, 34%) and vigabatrin‐to‐hormonal (9/26, 35%) groups, followed by vigabatrin‐to‐nonstandard (3/10, 30%), hormonal‐to‐hormonal (4/22, 18%), and hormonal‐to‐nonstandard (1/30, 3.3%). Compared to the hormonal‐to‐vigabatrin group (reference), fewer infants had remission in the hormonal‐to‐nonstandard group (OR = .07, 95% confidence interval [CI] = .01–.53), and there was a trend toward fewer infants in the hormonal‐to‐hormonal group (OR = .43, 95% CI = .13–1.4, p = .17). Following initial hormonal treatment, the number needed to treat was three infants for one additional infant to have remission when treated with vigabatrin compared to nonstandard therapy as the second treatment. Significance This updated analysis with an expanded sample size provided power for additional subgroup analysis. Overall response rates were low, and at best only one third had remission after second treatment. Results support a clinical strategy of switching mechanism of action when selecting a second medication for epileptic spasms (i.e., use vigabatrin after hormonal therapy, or hormonal therapy after vigabatrin). Our findings also support the use of standard over nonstandard therapies.
Preanalytical variables and analytes in liquid biopsy approach for brain tumors: A comprehensive review and recommendations from the RANO Group and the Brain Liquid Biopsy Consortium
Bettegowda, Chetan , Noushmehr, Houtan , Affinito, Alessandra , Ahluwalia, Manmeet S. , Ansorge, Olaf , Ayasoufi, Katayoun , Bagley, Stephen , Barnholtz‐Sloan, Jill S. , Brandsma, Dieta , Brodie, Chaya , Castro, Ana Valeria , Chang, Susan M. , Daher, Ahmad , Datta, Vineet , French, Pim J. , Golebiewska, Anna , Holdhoff, Matthias , LeBlang, Suzanne , Melin, Beatrice , Moulière, Florent , O’Leary, Claire , Robinson, Stephen , Sol, Nik , Vogelbaum, Michael A. , Walbert, Tobias , Watts, Colin , Wen, Patrick Y. , Wykes, Victoria , Yip, Stephen , Short, Susan , Barnholtz-Sloan, Jill S , Best, Myron , Brandsma, Dieta , Brüning-Richardson, Anke , Chang, Susan Marina , Condorelli, Gerolama , Daher, Ahmad , de Groot, John , French, Pim J , Galanis, Evanthia , Golebiewska, Anna , Hamerlik, Petra , Hanemann, C Oliver , Holdhoff, Matthias , Huse, Jason T. , Khasraw, Mustafa , LeBlang, Suzanne , Melin, Beatrice , Rominiyi, Ola , Roncaroli, F , Rudà, Roberta , Sol, Nik , van den Bent, Martin J , Walbert, Tobias , Watts, Colin , Weiss, Tobias , Weller, Michael , Wykes, Victoria , Yip, Stephen , Short, Susan C , Soffietti, Riccardo , Noushmehr, Houtan , Ayasoufi, Katayoun , Ahluwalia, Manmeet S , Bettegowda, Chetan , Groot, John de , Galanis, Evanthia , Hamerlik, Petra , Hanemann, C. Oliver , Khasraw, Mustafa , Rak, Janusz , Ray, Amitava, Roncaroli, Federico , Seoane, Joan , Bent, Martin J. van den , Wen, Patrick Yung , Soffietti, Riccardo

Mayo Clinic

Neuro-Oncology | June 16, 2025 | Volume: 27 | Issue: 10 | Pages: 2496-2513

10.1093/neuonc/noaf140 | PMID 40884415 Get It

Abstract This review explores the pivotal role of preanalytical variables in bringing liquid biopsy approaches into the clinic for brain tumors. Preanalytical variables encompass a range of critical issues, from blood sample collection and handling to the impact of tumor heterogeneity and patient-specific factors. These variables introduce challenges such as false positives, false negatives, and variability in the analysis of tumor signals, which can hinder the diagnostic and prognostic utility of liquid biopsies. Understanding the nuances of preanalytical variables is essential for the successful implementation of liquid biopsy in clinical settings. This paper delves into strategies aimed at mitigating the influence of preanalytical variables by emphasizing the importance of standardized sample collection protocols, optimized sample processing and storage, quality control measures, and the integration of multiple liquid biopsy modalities.
Bronchoscopic lung volume reduction: model for assisted target lobe selection
Hostetter, Logan , Brown, Leah M, Rajagopalan, Srinivasan , Dulohery-Scrodin, Megan, Edell, Eric S. , Lester, Michael , Maldonado, Fabien , Lentz, Robert J. , Bartholmai, Brian J. , Peikert, Tobias, Dulohery-Scrodin, Megan M, Bartholmai, Brian J , Brown, Leah M

Mayo Clinic

BMJ Open Respiratory Research | June 5, 2025 | Volume: 12 | Issue: 1 | Pages: e002903

10.1136/bmjresp-2024-002903 | PMID 40473270 Get It

Introduction Bronchoscopic lung volume reduction with endobronchial valves (EBV) is an effective procedure for patient with severe emphysema to improve lung function, exercise tolerance, dyspnoea and quality of life. Optimisation of patient and treatment lobe selection is essential for successful EBV outcomes. While clinical selection criteria are rigorous, many centres use a multidisciplinary team and rely on previous clinical experience for the selection process. To aid objective clinical decision making, we present a mathematical model to facilitate patient and target lobe selection. Methods A multidisciplinary team reviewed quantitative high-resolution computed tomography (HRCT) analysis from 119 patients to select candidates for EBV and to select a treatment lobe. Two logistic regression models, (1) candidacy for EBV placement and (2) target-lobe selection, were developed based on the normalised distributions of the four quantitative HRCT variables (fissure completeness score, per cent of voxel density with HU < −910 and HU < −950, and lobar volumes) across all five lung lobes. An external cohort of 50 patients (25 candidates and 25 non-candidates) was used to validate the prediction model. Results Performance measures of the training cohort demonstrated an area under the curve (AUC) of 0.91, accuracy of 81%, sensitivity of 93% and specificity of 78% compared with the multidisciplinary teams’ target lobe selection. The validation cohort demonstrated an AUC of 0.89, accuracy of 84%, sensitivity of 88% and specificity of 83% compared with the multidisciplinary team decision making. Conclusions Endobronchial valve lung volume reduction remains a potent palliative measure to improve quality of life in patients with hyperinflated emphysema. Our model for target lobe selection harnesses the multidisciplinary experience at a tertiary care centre to objectively select candidates and target lobes to assist clinicians’ decision making. Future studies investigating prediction of lobar collapse and functional improvement after target lobe selection using our model are needed.
A multicenter, propensity score-matched analysis of functional outcomes and recanalization success with or without Trevo for Medium and distal vessel occlusion
Siegler, James E. , Koneru, Manisha , Shaikh, Hamza, Salim, Hamza , Musmar, Basel , Adeeb, Nimer , Yedavalli, Vivek , Tjoumakaris, Stavropoula , Henninger, Nils , Sundararajan, Sri Hari , Tan, Benjamin Yong‐Qiang , Heit, Jeremy J , Regenhardt, Robert W. , Kass‐Hout, Tareq , Fiehler, Jens, Puri, Ajit S , Dyzmann, Christian , Barreau, Xavier, Renieri, Leonardo, Filipe, João Pedro , Harker, Pablo, Marotta, Thomas R. , Spears, Julian , Biswas, Arundhati , Clarençon, Frédéric, Abdalkader, Mohamad , Varela, Ricardo , Baker, Amanda , Altschul, David , Gonzalez, Nestor R. , Möhlenbruch, Markus A, Costalat, Vincent, Gory, Benjamin, Stracke, Christian Paul , Hecker, Constantin, Liebeskind, David S. , Alexandre, Andrea , Tancredi, Illario , Faizy, Tobias D. , Kalsoum, Erwah , Lubicz, Boris , Patel, Aman B. , Khalife, Jane, Rana, Ankit, Guenego, Adrien , Investigators, for the MAD MT, Heit, Jeremy J. , Salim, Hamza , Tjoumakaris, Stavropoula , Henninger, Nils , Kühn, Anna Luisa , Ghozy, Sherief , Scarcia, Luca , Regenhardt, Robert W , Morsi, Rami Z , Vigilante, Nicholas , Rouchaud, Aymeric , Essibayi, Muhammed Amir , Dyzmann, Christian , Colasurdo, Marco , Filipe, João Pedro , Alexandru Radu, Răzvan , Ota, Takahiro , Jabbour, Pascal , Klein, Piers , Nguyen, Thanh N , Altschul, David J , Gonzalez, Nestor R , Griessenauer, Christoph J , Liebeskind, David S. , Tancredi, Illario , Guenego, Adrien , Dmytriw, Adam A , Heit, Jeremy J , Musmar, Basel , Yedavalli, Vivek S , Siegler, James E , Tan, Benjamin Yq , Alexandre, Andrea M , Varela, Ricardo , Daraghma, Motaz , Kühn, Anna Luisa , Ghozy, Sherief , Morsi, Rami Z. , Cancelliere, Nicole M , Bernstock, Joshua D. , Rouchaud, Aymeric , Sheth, Sunil A , Essibayi, Muhammed Amir , Colasurdo, Marco , Barreau, Xavier , Renieri, Leonardo , Harker, Pablo , Radu, Răzvan Alexandru , Mowla, Ashkan , Jabbour, Pascal , Clarençon, Frédéric , Klein, Piers , Nguyen, Thanh N. , Möhlenbruch, Markus , Costalat, Vincent , Gory, Benjamin , Hecker, Constantin , Griessenauer, Christoph J. , Pedicelli, Alessandro , Mendes Pereira, Vitor , Khalife, Jane , Dmytriw, Adam A. , Investigators, for the MAD MT

Mayo Clinic

Interventional Neuroradiology | May 21, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15910199251341603 | PMID 40398470 Get It

Background Endovascular therapy (EVT) for stroke due to distal or medium vessel occlusion (DMVO) is safe. Due to the distinct anatomical characteristics of DMVOs, further evaluation of EVT is crucial to determine which devices may yield better outcomes. Methods A retrospective analysis of adults with DMVO treated in 37 centers (11 countries) was queried. The primary outcome of favorable shift in 90-day modified Rankin Scale (mRS) was compared between patients treated with Trevo versus other devices on first pass using 1:1 propensity score matching (PSM) with multivariable adjustment. Secondary outcomes included the number of pass attempts, final thrombolysis in cerebral infarction (TICI) score 2b-3, symptomatic intracranial hemorrhage (sICH), improvement in National Institutes of Health Stroke Scale (NIHSS) at 24h, and 90-day mortality. Results Of the 1115 included patients, 264 (24%) were treated with Trevo (PSM cohort of 261 per group). Trevo use was not associated with a favorable 90-day mRS shift (proportional odds ratio [OR] 1.10, 95% confidence interval [CI] 0.80–1.51). Trevo was associated with fewer passes (adjusted β=-0.25, 95% CI −0.48 - −0.03), higher odds of TICI 2b-3 (adjusted OR 1.97, 95% CI 1.11–3.49), and a greater 24h NIHSS improvement (adjusted β= −1.74, 95% CI −3.11 - −0.36), with no difference in sICH or mortality (p>0.05). Results were similar in sensitivity analyses. Conclusions We observed no safety concerns with Trevo as compared to other EVT devices for DMVO recanalization. There was a signal of better technical efficacy and early clinical improvement.